Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

The MEK Inhibitor Trametinib Enhances Diverse T Cell Reconstitution with Suppressing Xenogeneic Graft-Versus-Host-Disease

Hidekazu Itamura, MD PhD, Hiroyuki Muranushi, MD, Takero Shindo, MD PhD, Kazutaka Kitaura, DVM, PhD, Seiji Okada, MD PhD, Tadasu Shin-I, PhD, Ryuji Suzuki, DVM, PhD, Akifumi Takaori-Kondo, MD PhD, Shinya Kimura, MD PhD

Blood (2019) 134 (Supplement_1): 1929.

https://doi.org/10.1182/blood-2019-128913

Published: 2019

Journal Articles

Efficacy of OR21, a Novel Oral Demethylating Agent in Chronic Myeloid Leukemia

Kazuharu Kamachi, MD, Hiroshi Ureshino, MD, Nao Yoshida, MD, Yuki Kurahashi, Tatsuro Watanabe, PhD, Seiji Okada, MD PhD, Shinya Kimura, MD PhD

Blood (2019) 134 (Supplement_1): 5365.

https://doi.org/10.1182/blood-2019-125460

Published: 2019

Journal Articles

The Presence and Possible Role of Virus-Host Chimeric Transcripts in Adult T-Cell Leukemia-Lymphoma

Hiroo Katsuya, MD, Paola Miyazato, PhD, Saiful Islam, Benjy Jek Yang Tan, MD, Yuki Inada, Misaki Matsuo, Takaharu Ueno, Masahito Tokunaga, MD PhD, Hiroyuki Hata, MD PhD, Makoto Yamagishi, PhD, Jun-Ichi Fujisawa, Toshiki Watanabe, MD, PhD, Kaoru Uchimaru, MD, PhD, Atae Utsunomiya, MD, Shinya Kimura, MD PhD, Yorifumi Satou, MD PhD

Blood (2019) 134 (Supplement_1): 2779.

https://doi.org/10.1182/blood-2019-124361

Published: 2019

Journal Articles

Aberrant Regional DNA Hypermethylation As a Preventive and Therapeutic Target for Adult T-Cell Leukemia-Lymphoma

Tatsuro Watanabe, PhD, Hiroshi Ureshino, MD, Yuki Kurahashi, Yuki Fukuda-Kurahashi, Satoshi Yamashita, PhD, Toshikazu Ushijima, MD PhD, Seiji Okada, MD PhD, Eisaburo Sueoka, MD PhD, Shinya Kimura, MD PhD

Blood (2018) 132 (Supplement 1): 4175.

https://doi.org/10.1182/blood-2018-99-117536

Published: 2018

Journal Articles

Automatic Digital Quantification of Bone Marrow Myeloma Volume in Appendicular Skeletons — Clinical Implications and Prognostic Significance

Yuki Nishida, Shinya Kimura, MD, PhD, Hideaki Mizobe, Junta Yamamichi, Kensuke Kojima, MD PhD, Atsushi Kawaguchi, PhD, Manabu Fujisawa, MD, Kosei Matsue, MD PhD

Blood (2017) 130 (Supplement 1): 4401.

https://doi.org/10.1182/blood.V130.Suppl_1.4401.4401

Published: 2017

Journal Articles

IFN-α Upregulates the Expression of C/EBPβ and Induces Myeloid Differentiation and Exhaustion of CD34 + CML Stem Cells

Asumi Yokota, PhD, Hideyo Hirai, MD, Atsushi Sato, MD, Naoka Kamio, MD, Yoshihiro Hayashi, MD PhD, Yasuo Miura, MD PhD, Shinya Kimura, MD, PhD, Taira Maekawa, MD PhD

Blood (2017) 130 (Supplement 1): 2863.

https://doi.org/10.1182/blood.V130.Suppl_1.2863.2863

Published: 2017

Journal Articles

Preclinical Anti-Lymphoma Activity of the BCL-2 BH4 Domain Antagonist Bda-366 in Mantle Cell Lymphoma

Sho Okamoto, MD, Aya Maeda, Shinya Kimura, MD, PhD, Kensuke Kojima, MD PhD

Blood (2017) 130 (Supplement 1): 3847.

https://doi.org/10.1182/blood.V130.Suppl_1.3847.3847

Published: 2017

Journal Articles

Downregulation of BMI-1 By the Small Molecule PTC596 Induces Mitochondrial Apoptosis in Mantle Cell Lymphoma

Kensuke Kojima, MD PhD, Aya Maeda, Sho Okamoto, MD, Yuki Nishida, Cao Liangl, Marla Weetall, PhD, Art Branstrom, PhD, Shinya Kimura, MD, PhD

Blood (2017) 130 (Supplement 1): 1263.

https://doi.org/10.1182/blood.V130.Suppl_1.1263.1263

Published: 2017

Journal Articles

Molecular Mechanism for Synergistic Anti-Leukemic Activity of Tyrosine Kinase Inhibitors and Glucocorticoids Against Ph+ALL

Meixian Huang, MD, Takeshi Inukai, MD, PhD, Keiko Kagami, BD, Masako Abe, BD, Tamao Shinohara, MD, Atsushi Watanabe, MD PhD, Koshi Akahane, MD PhD, Shinpei Somazu, MD, Hiroko Oshiro, MD PhD, Kumiko Goi, MD PhD, Yasuhiro Maeda, MD PhD, Seiichi Okabe, MD PhD, Shinya Kimura, MD, PhD, Kanji Sugita, MD, PhD

Blood (2016) 128 (22): 1059.

https://doi.org/10.1182/blood.V128.22.1059.1059

Published: 2016

Journal Articles

The Pathophysiological Significance and Therapeutic Targeting of PPM1D-Mediated Signaling in Mantle Cell Lymphoma

Kensuke Kojima, MD, PhD, Aya Maeda, Yuki Nishida, MD, Shinya Kimura, MD, PhD

Blood (2016) 128 (22): 2760.

https://doi.org/10.1182/blood.V128.22.2760.2760

Published: 2016

Journal Articles

Synergistic Cytotoxicity Between Panobinostat and Ponatinib In Imatinib-Resistant Chronic Myeloid Leukemia Cells

Yasufumi Matsuda, MD, Takahiro Yamauchi, MD, PhD, Kanako Uzui, Eiju Negoro, MD, Koji Morinaga, MD., PhD., Hiroko Shigemi, MD, Rie Nishi, Shinya Kimura, MD, PhD, Taira Maekawa, MD, PhD, Takanori Ueda, MD, PhD

Blood (2013) 122 (21): 3989.

https://doi.org/10.1182/blood.V122.21.3989.3989

Published: 2013

Journal Articles

Metabolic Shift In Hypoxia-Adapted CML Cells and Mechanisms Of Acquired Dasatinib Resistance Uncovered By Proteomic iTRAQ Profiling

Yoko Tabe, MD, PhD, Linhua Jin, PhD, Hiroko Iwanami, Hiromichi Matsushita, MD, PhD, Saiko Kazuno, Tsutomu Fujimura, Takashi Ueno, Takashi Miida, MD, PhD, Michael Andreeff, MD, PhD, Marina Konopleva, MD, PhD, Shinya Kimura, MD, PhD

Blood (2013) 122 (21): 3991.

https://doi.org/10.1182/blood.V122.21.3991.3991

Published: 2013

Journal Articles

Discontinuation Of Dasatinib In Patients With CML Who Have Maintained Complete Molecular Response For At Least One Year: Results From a Prospective Discontinuation (DADI) Trial

Blood (2013) 122 (21): 3998.

https://doi.org/10.1182/blood.V122.21.3998.3998

Published: 2013

Journal Articles

Nilotinib Following Molecular Suboptimal Response (SoR) To Imatinib In Japanese Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): 12 Month Follow-Up From The SENSOR Study

Blood (2013) 122 (21): 2729.

https://doi.org/10.1182/blood.V122.21.2729.2729

Published: 2013

Journal Articles

Induction Of p53 Transcription and Apoptosis By XPO1 Inhibition In Mantle Cell Lymphoma

Mariko Yoshimura, MD, Jo Ishizawa, MD, PhD, Archana Dilip, MS, Sharon Shacham, PhD, MBA, Michael Kauffman, MD, PhD, Yoko Tabe, MD, PhD, Shinya Kimura, MD, PhD, Michael Andreeff, MD, PhD, Kensuke Kojima, MD, PhD

Blood (2013) 122 (21): 3825.

https://doi.org/10.1182/blood.V122.21.3825.3825

Published: 2013

Journal Articles

Sustained Molecular Response with Maintenance Dose of Interferon Alfa After Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia

Kensuke Usuki, MD, PhD, Nozomi Yusa, Akira Hangaishi, MD, PhD, Rieko Sekine, MD, PhD, Kenshi Suzuki, MD, PhD, Shinya Kimura, MD, PhD, Arinobu Tojo, MD, PhD.

Blood (2012) 120 (21): 1684.

https://doi.org/10.1182/blood.V120.21.1684.1684

Published: 2012

Journal Articles

Analysis of Dasatinib-Induced Molecular Mechanisms of Apoptosis in Hypoxia-Adopted CML Cells Utilizing Quantitative Proteomics Technology.

Yoko Tabe, MD, PhD, Linhua Jin, PhD, Hiroko Iwanami, Saiko Kazuno, Tsutomu Fujimura, Hiromichi Matsushita, MD, PhD, Takashi Ueno, Takashi Miida, MD, PhD, Michael Andreeff, MD, PhD, Marina Konopleva, MD, PhD, Shinya Kimura, MD, PhD

Blood (2012) 120 (21): 2773.

https://doi.org/10.1182/blood.V120.21.2773.2773

Published: 2012

Journal Articles

Antiproliferative Effect of 2-Hydroxypropyl-β-Cyclodextrin (HP-β-CyD) Against Chronic Myeloid Leukemia In Vitro and In Vivo .

Masako Yokoo, MD, Yasushi Kubota, MD, PhD, Sakiko Mochinaga, Aya Maeda, Tatsuo Ichinohe, MD, PhD, Hiroshi Fujito, Taishi Higashi, Keiichi Motoyama, Hidetoshi Arima, Tetsumi Irie, Shinya Kimura, MD, PhD

Blood (2012) 120 (21): 2442.

https://doi.org/10.1182/blood.V120.21.2442.2442

Published: 2012

Journal Articles

Combination Effects of Nilotinib and Zoledronic Acid On Chronic Myeloid Leukemia Are Canceled in the Co-Culture System Which Mimic the Bone Marrow Microenvironment.

Masako Yokoo, MD, Yasushi Kubota, MD, PhD, Tatsuo Ichinohe, MD, PhD, Shinya Kimura, MD, PhD

Blood (2012) 120 (21): 2459.

https://doi.org/10.1182/blood.V120.21.2459.2459

Published: 2012

Journal Articles

PD0332991, a CDK4/6 Inhibitor, Has An Anti-Leukemic Activity Against Lymphoid Crisis of CML and Ph+ALL Even with T315I Mutation in BCR-Abl; in Vitro Analysis

Atsushi Nemoto, MD, PhD, Takeshi Inukai, MD, PhD, Koshi Akahane, MD, PhD, Hiroko Honna- Oshiro, MD, PhD, Kumiko Goi, MD, PhD, Keiko Kagami, Yasuhiro Maeda, MD, PhD, Tetsuzo Tauchi, M.D., Shinya Kimura, MD, PhD, Kanji Sugita, MD, PhD

Blood (2011) 118 (21): 1511.

https://doi.org/10.1182/blood.V118.21.1511.1511

Published: 2011

NARROW

The MEK Inhibitor Trametinib Enhances Diverse T Cell Reconstitution with Suppressing Xenogeneic Graft-Versus-Host-Disease

Efficacy of OR21, a Novel Oral Demethylating Agent in Chronic Myeloid Leukemia

The Presence and Possible Role of Virus-Host Chimeric Transcripts in Adult T-Cell Leukemia-Lymphoma

Aberrant Regional DNA Hypermethylation As a Preventive and Therapeutic Target for Adult T-Cell Leukemia-Lymphoma

Automatic Digital Quantification of Bone Marrow Myeloma Volume in Appendicular Skeletons — Clinical Implications and Prognostic Significance

IFN-α Upregulates the Expression of C/EBPβ and Induces Myeloid Differentiation and Exhaustion of CD34 + CML Stem Cells

Preclinical Anti-Lymphoma Activity of the BCL-2 BH4 Domain Antagonist Bda-366 in Mantle Cell Lymphoma

Downregulation of BMI-1 By the Small Molecule PTC596 Induces Mitochondrial Apoptosis in Mantle Cell Lymphoma

Molecular Mechanism for Synergistic Anti-Leukemic Activity of Tyrosine Kinase Inhibitors and Glucocorticoids Against Ph+ALL

The Pathophysiological Significance and Therapeutic Targeting of PPM1D-Mediated Signaling in Mantle Cell Lymphoma

Synergistic Cytotoxicity Between Panobinostat and Ponatinib In Imatinib-Resistant Chronic Myeloid Leukemia Cells

Metabolic Shift In Hypoxia-Adapted CML Cells and Mechanisms Of Acquired Dasatinib Resistance Uncovered By Proteomic iTRAQ Profiling

Discontinuation Of Dasatinib In Patients With CML Who Have Maintained Complete Molecular Response For At Least One Year: Results From a Prospective Discontinuation (DADI) Trial

Nilotinib Following Molecular Suboptimal Response (SoR) To Imatinib In Japanese Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): 12 Month Follow-Up From The SENSOR Study

Induction Of p53 Transcription and Apoptosis By XPO1 Inhibition In Mantle Cell Lymphoma

Sustained Molecular Response with Maintenance Dose of Interferon Alfa After Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia

Analysis of Dasatinib-Induced Molecular Mechanisms of Apoptosis in Hypoxia-Adopted CML Cells Utilizing Quantitative Proteomics Technology.

Antiproliferative Effect of 2-Hydroxypropyl-β-Cyclodextrin (HP-β-CyD) Against Chronic Myeloid Leukemia In Vitro and In Vivo .

Combination Effects of Nilotinib and Zoledronic Acid On Chronic Myeloid Leukemia Are Canceled in the Co-Culture System Which Mimic the Bone Marrow Microenvironment.

PD0332991, a CDK4/6 Inhibitor, Has An Anti-Leukemic Activity Against Lymphoid Crisis of CML and Ph+ALL Even with T315I Mutation in BCR-Abl; in Vitro Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only